Report
Ingird Gafanhão

Takeaways from CMD - safety is back on the spotlight

The CMD focus was on obe-cel with a recap of the medical need in adult r/r ALL, obe-cel data available to date, health economics, and initial commercial considerations. As usual, there were a few key points highlighted for obe-cel including its extended persistency, consistency of outcomes across t
Underlying
Autolus Therapeutics ADS

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Ingird Gafanhão

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch